^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Sarcoma
    Drug:ozekibart (INBRX-109) (TRAIL R2 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Inhibrx Press Release
    Title:

    Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

    Published date:
    01/13/2021
    Excerpt:
    Inhibrx, Inc...today the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.